I help growth-oriented life sciences companies, investors, and academic institutions maximize IP asset value through strategic patent portfolio development counseling in transactions and disputes.
Dr. Philip Choi has obtained numerous domestic and foreign patents for corporate, academic and independent research institutions in a wide range of technical areas, including the fields of biotechnology, biochemistry, materials science, biomedicine and pharmaceuticals.
Philip specializes in helping academic institutions with cost-effective drafting and prosecution of pre-licensed patent applications, as well as representing institutional interests in the licensing and marketing of intellectual property available for technology transfer. In addition, he has extensive experience consulting on patent enforcement and litigation matters from discovery and deposition phases through to trial.
Philip brings extensive technical accomplishments in the life sciences to his intellectual property practice. As a doctoral student in the laboratory of Dr. Catherine Dulac at Harvard University and the Howard Hughes Medical Institute, he investigated the functions of microRNAs during the developmental regulation of olfactory neurogenesis in both mouse and zebrafish model systems using transgenic, exo utero electroporation and morpholino-mediated gene knockdown strategies. Philip also worked as a Howard Hughes Medical Institute undergraduate researcher with Dr. Robert Goldberg at the University of California, Los Angeles. In that capacity, he explored the role of morphogenetic factors involved in cell specification events that dictate differential developmental pathways during seed development using microarray, bioinformatics and reverse genetic strategies. Philip was a technology specialist and registered patent agent with the firm prior to and during his attendance of law school.
Cochleate formulations comprising hydrophilic active pharmaceutical ingredients (International Patent Appl. Publ. No. WO 12/151517)
Ceramide-based cancer treatment methods (International International Patent Appl. Publ. No. WO 12/138739)
Chemokine receptor antagonist-based methods for treating cardiac and neurological disorders (International Patent Appl. Publ. No. WO 12/097062)
Devices and methods for treating heart failure using transient dyssynchrony (International Patent Appl. Publ. No. WO 12/064743)
Alphavirus infection inhibiting methods (International Patent Appl. Publ. No. WO 12/037485)
Global chromosomal aberration score assays and methods for predicting anti-cancer treatment efficacy (International Patent Appl. Publ. No. WO 12/027224)
Automated in situ contaminant detection system (U.S. Patent Appl. Publ. No. 2012-0105830)
Pseudovirion-based methods for enhancing antigen-specific immune responses (International Patent Appl. Publ. No. WO11/017162)
Oncolytic virus-based methods for enhancing antigen-specific immune responses (International Patent Appl. Publ. No. WO10/129339
Brown fat cell differentiation activating methods (International Patent Appl. Publ. No. WO10/080985)
Hepatic disorder diagnostic, prognostic, and treatment methods (International Patent Appl. Publ. No. WO10/045470)
MicroRNA-based compositions and methods useful for diagnosing, prognosing, and treating inflammatory bowel diseases (International Patent Appl. Publ. No. WO09/120877)
Regulatable protein compositions (International Patent Appl. Publ. No. WO09/002607)
Counsel for the Dana-Farber Cancer Institute in five U.S. patent interferences related to PD-L1 immunomodulatory technology.
Technical lead for scientific matters in defense of an International Trade Commission investigation leading to invalidity of all asserted claims and unenforceability of an asserted patent (see Ajinomoto Co., Inc. v. ITC, 597 F.3d 1267 (2010)).
Litigation team member representing Becton Dickinson in a patent dispute with Gen-Probe involving methods of automating nucleic acid diagnostic assays.
Litigation team member representing Biogen Idec in a patent dispute with Sanofi-Aventis Deutschland involving human CMV regulatory sequence compositions.
PROFESSIONAL EXPERIENCE
Teaching Fellow, Molecular Biology and Molecular Mechanisms of Gene Control, Harvard University
Publications
Choi P.S. et al. Members of the miRNA-200 Family Regulate Olfactory Neurogenesis. Neuron, 57(1):41-55 (2007)
Foley Hoag Publications
Honors & Involvement
HONORS
Received Harvard University Certificate of Distinction in Teaching
Named National Science Foundation (NSF) Pre-Doctoral Fellow
Named UCLA Regents Scholar (Full-Tuition Scholarship)
Named Howard Hughes Medical Institute Undergraduate Researcher
INVOLVEMENT
Pro bono work to secure patent rights and provide intellectual property advice for a non-profit marine research laboratory
Boston Patent Law Association, Member
Association of University Technology Managers, Member
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.